导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.04% | 1237/4766 |
| 近一周 | -0.75% | 1817/5457 |
| 近一月 | -6.21% | 2970/5411 |
| 近一季 | -10.01% | 3197/5229 |
| 近半年 | -2.26% | 2265/4923 |
| 近一年 | 8.68% | 1155/4393 |
| 近两年 | 80.16% | 832/2948 |
| 近三年 | 42.87% | 684/2248 |
| 成立以来 | 40.28% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.20% 1017/4961 |
19.80% 1275/5312 |
- - |
- - |
| 2025 | 32.96% 1141/4813 |
2.31% 1407/3635 |
1.97% 1977/4076 |
25.86% 1375/4524 |
1.25% 1451/4813 |
| 2024 | 7.54% 1648/3463 |
-2.68% 1405/2808 |
-5.38% 1707/3014 |
16.99% 1295/3129 |
-0.18% 1337/3463 |
| 2023 | -5.74% 770/2656 |
8.11% 496/2280 |
-4.11% 1052/2385 |
-4.62% 1183/2515 |
-4.67% 1136/2655 |
| 2022 | -18.38% 701/2207 |
-13.98% 881/1919 |
3.43% 1154/2016 |
-10.78% 451/2113 |
2.81% 829/2208 |
| 2021 | 18.40% 208/1822 |
-1.30% 463/1255 |
9.99% 502/1330 |
5.25% 285/1466 |
3.63% 412/1822 |
| 2020 | - - |
- - |
- - |
- - |
3.87% 885/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 天弘中证500ETF VS. 长安沪深300非周期A(740101) |